Drug intelligence / Profile preview

SP-6-37

Development stage: Preclinical
Lead developer: Rosalind Franklin University
Modality: Small Molecules

Overview

SP-6-37 is a novel chromene analog developed as a small-molecule microtubule destabilizer for the treatment of ovarian cancer. It functions by inhibiting tubulin polymerization, which disrupts the dynamic instability of microtubules required for cell division, ultimately triggering apoptosis. Research from the Rosalind Franklin University of Medicine and Science has shown that SP-6-37 is effective against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines (such as A2780, SKOV-3, TOV112D, and OVCAR-3), while maintaining low cytotoxicity toward normal ovarian epithelial cells.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SP-6-37.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-6-37.

Explore the full profile